The most common type of arthritis, osteoarthritis affects over 15 million people in the United States. Working in collaboration, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute on Aging (NIA), the and the private sector are striving to improve the efficiency of drug development and clinical trials for the treatment of osteoarthritis. In 2009, the Osteoarthritis Initiative (OAI) began extended follow-up of its study cohort for an additional six years (OAI II).

The goal of OAI II is to gain a better understanding of the natural history and course of both early and established knee osteoarthritis and its determinants, as well as to help accrue additional endpoints for clinical investigation across the spectrum of the disease.  Identifying early predictive biomarkers of osteoarthritis could lead to more efficient and faster clinical trials by identifying higher risk individuals and ultimately, to the development of drug treatments to slow progression or modify this disabling disease.

Get involved. Partner with us.

To learn more about partnership opportunities with the Osteoarthritis Initiative II, contact us:

Julie Wolf-Rodda, Director of Partnership Development
Phone: (301) 402-5311
E-mail: jwolf-rodda [at] fnih [dot] org